Peptide-Based Therapies for Neurodegenerative Diseases

Peptide-Based Therapies for Neurodegenerative Diseases

<table class="infobox infobox-therapeutic">
<tr>
<th class="infobox-header" colspan="2">Peptide-Based Therapies for Neurodegenerative Diseases</th>
</tr>
<tr>
<td class="label">Drug</td>
<td>Sequence/Target</td>
</tr>
<tr>
<td class="label">Brevigen</td>
<td>[Aβ42](/proteins/amyloid-beta) C-terminal</td>
</tr>
<tr>
<td class="label">CAD106</td>
<td>Aβ1-6 carrier</td>
</tr>
<tr>
<td class="label">ACI-35</td>
<td>Phospho-[tau](/proteins/tau) liposome</td>
</tr>
<tr>
<td class="label">Drug</td>
<td>Target</td>
</tr>
<tr>
<td class="label">Davunetide</td>
<td>NAP/tau</td>
</tr>
<tr>
<td class="label">Peptide 5</td>
<td>[α-synuclein](/proteins/alpha-synuclein)</td>
</tr>
<tr>
<td class="label">Trial</td>
<td>Peptide</td>
</tr>
<tr>
<td class="label">NCT04637438</td>
<td>Lu AF20513</td>
</tr>
<tr>
<td class="label">NCT04562870</td>
<td>davunetide</td>
</tr>
<tr>
<td class="label">NCT05413317</td>
<td>peptide X</td>
</tr>
<tr>
<td class="label">Drug</td>
<td>Reason</td>
</tr>
<tr>
<td class="label">Brevigen</td>
<td>Insufficient efficacy</td>
</tr>
<tr>
<td class="label">Bapineuzumab</td>
<td>ARIA, no cognitive benefit</td>
</tr>
<tr>
<td class="label">Semaglintide</td>
<td>BBB penetration issues</td>
</tr>
</table>

Introduction

...

Peptide-Based Therapies for Neurodegenerative Diseases

<table class="infobox infobox-therapeutic">
<tr>
<th class="infobox-header" colspan="2">Peptide-Based Therapies for Neurodegenerative Diseases</th>
</tr>
<tr>
<td class="label">Drug</td>
<td>Sequence/Target</td>
</tr>
<tr>
<td class="label">Brevigen</td>
<td>[Aβ42](/proteins/amyloid-beta) C-terminal</td>
</tr>
<tr>
<td class="label">CAD106</td>
<td>Aβ1-6 carrier</td>
</tr>
<tr>
<td class="label">ACI-35</td>
<td>Phospho-[tau](/proteins/tau) liposome</td>
</tr>
<tr>
<td class="label">Drug</td>
<td>Target</td>
</tr>
<tr>
<td class="label">Davunetide</td>
<td>NAP/tau</td>
</tr>
<tr>
<td class="label">Peptide 5</td>
<td>[α-synuclein](/proteins/alpha-synuclein)</td>
</tr>
<tr>
<td class="label">Trial</td>
<td>Peptide</td>
</tr>
<tr>
<td class="label">NCT04637438</td>
<td>Lu AF20513</td>
</tr>
<tr>
<td class="label">NCT04562870</td>
<td>davunetide</td>
</tr>
<tr>
<td class="label">NCT05413317</td>
<td>peptide X</td>
</tr>
<tr>
<td class="label">Drug</td>
<td>Reason</td>
</tr>
<tr>
<td class="label">Brevigen</td>
<td>Insufficient efficacy</td>
</tr>
<tr>
<td class="label">Bapineuzumab</td>
<td>ARIA, no cognitive benefit</td>
</tr>
<tr>
<td class="label">Semaglintide</td>
<td>BBB penetration issues</td>
</tr>
</table>

Introduction

Peptide Based Therapies For Neurodegenerative Diseases is a treatment approach for neurodegenerative diseases. This page provides comprehensive information about its mechanism of action, clinical evidence, and therapeutic potential.

Overview

Peptides are short chains of amino acids (typically 2-50 residues) that can:

• Mimic or block protein-protein interactions
• Cross cell membranes with appropriate design
• Target specific protein aggregates
• Modulate receptor function

Approved Peptide Therapies

Alzheimer's Disease

Parkinson's Disease

Peptide Classes

1. Aggregation Inhibitors

Mechanism: Bind to misfolded proteins, preventing oligomerization and fibril formation.

Examples:

• [Aβ](/proteins/amyloid-beta) aggregation inhibitors: Peptides targeting Aβ42 hydrophobic regions[@inhibitors2021]
• α-synuclein inhibitors: Peptide fragments mimicking N-terminal region[@computing2020]
• [Tau](/proteins/tau) aggregation inhibitors: PHF6 motif peptides[@tau2019]

Challenges: [Blood-brain barrier](/entities/blood-brain-barrier) penetration, stability, delivery.

2. Neuroprotective Peptides

Mechanism: Promote neuronal survival, reduce [apoptosis](/entities/apoptosis), support synaptic function.

Examples:

• BDNF-mimetic peptides: Activate TrkB signaling[@bdnf2018]
• GDNF-mimetic peptides: Support dopaminergic [neurons](/entities/neurons)[@gdnf2017]
• NAP (Davunetide): Microtubule stabilization[@nap2016]

3. Cell-Penetrating Peptides (CPPs)

Mechanism: Cross cell membranes, deliver cargo to intracellular targets.

Examples:

• TAT fusion proteins: Deliver therapeutic proteins[@tat2020]
• Penetratin: CNS delivery platform[@penetratin2019]
• Arginine-rich peptides: Efficient cellular uptake[@arginine2021]

4. Antimicrobial Peptides (AMPs)

Mechanism: Native defense peptides with neuroprotective properties.

Examples:

• LL-37: Neuroinflammation modulation[@ref2018]
• Defensins: Microglial activation regulation[@defensins2019]

Research Directions

Stapled Peptides

• Helix stabilization increases stability
• Improved BBB penetration
• Enhanced target affinity[@stapled2020]

Cyclic Peptides

• Proteolytic stability
• Reduced clearance
• Constrained conformations[@cyclic2021]

Peptide-Drug Conjugates

• Targeted delivery
• Controlled release
• Combination therapy[@conjugates2022]

Clinical Trials

Active Trials

Failed Trials

Manufacturing

Challenges

• Scalable synthesis
• Purification protocols
• Formulation stability
• Cost of goods

Advances

• Solid-phase peptide synthesis
• Microwave-assisted synthesis
• Flow chemistry
• Recombinant expression

Future Perspectives

Emerging Technologies

• Computational design: AI-guided peptide optimization
• Self-assembling peptides: Sustained release depots
• Peptide arrays: Personalized medicine approaches
• Hybrid molecules: Peptide-small molecule chimeras

Combination Approaches

• Peptide + small molecule
• Peptide + antibody
• Peptide + cell therapy
• Peptide + gene therapy

Background

The study of Peptide Based Therapies For Neurodegenerative Diseases has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.

Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.

See Also

• Immunotherapies Overview
• Tau Immunotherapies
• Alpha-Synuclein Immunotherapies
• [Neurotrophic Factor Therapies](/therapeutics/neurotrophic-factor-therapies)
• [Alzheimer's Disease](/diseases/alzheimers-disease)
• [Parkinson's Disease](/diseases/parkinsons-disease)

External Links

• [ClinicalTrials.gov Peptide Search](https://clinicaltrials.gov)
• [Peptide Science Journal](https://www.mdpi.com/journal/peptides)
• [International Society for Peptide Science](https://www.ipspeptidescience.org)

References

Unknown, Aβ Aggregation (2020) (2020)

Unknown, CAD106 (2019) (2019)

Unknown, ACI-35 (2021) (2021)

Gozes et al, (2015) (2015)

Unknown, α-synuclein peptides (2022) (2022)

Unknown, Aβ inhibitors (2021) (2021)

Unknown, Computing approaches (2020) (2020)

Unknown, Tau aggregation (2019) (2019)

Unknown, BDNF mimetics (2018) (2018)

Unknown, GDNF analogs (2017) (2017)

Unknown, NAP (2016) (2016)

Unknown, TAT delivery (2020) (2020)

Unknown, Penetratin (2019) (2019)

Unknown, Arginine peptides (2021) (2021)

Unknown, LL-37 (2018) (2018)

Unknown, Defensins (2019) (2019)

Unknown, Stapled peptides (2020) (2020)

Unknown, Cyclic peptides (2021) (2021)

Unknown, Conjugates (2022) (2022)